These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 26690343

  • 1. Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014.
    van der Maas NA, Woudenberg T, Hahné SJ, de Melker HE.
    J Infect Dis; 2016 May 01; 213(9):1466-71. PubMed ID: 26690343
    [Abstract] [Full Text] [Related]

  • 2. A novel measles outbreak control strategy in the Netherlands in 2013-2014 using a national electronic immunization register: A study of early MMR uptake and its determinants.
    Nic Lochlainn LM, Woudenberg T, van Lier A, Zonnenberg I, Philippi M, de Melker HE, Hahné SJM.
    Vaccine; 2017 Oct 13; 35(43):5828-5834. PubMed ID: 28923422
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study.
    Woudenberg T, van der Maas NAT, Knol MJ, de Melker H, van Binnendijk RS, Hahné SJM.
    J Infect Dis; 2017 Apr 15; 215(8):1181-1187. PubMed ID: 28368471
    [Abstract] [Full Text] [Related]

  • 4. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.
    Vaccine; 2014 Feb 26; 32(10):1147-52. PubMed ID: 24440207
    [Abstract] [Full Text] [Related]

  • 5. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S, Thukral R, Chakarvarti A.
    Indian J Med Res; 2003 Nov 26; 118():183-6. PubMed ID: 14723482
    [Abstract] [Full Text] [Related]

  • 6. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
    He H, Chen E, Chen H, Wang Z, Li Q, Yan R, Guo J, Zhou Y, Pan J, Xie S.
    Vaccine; 2014 Jun 30; 32(31):4001-5. PubMed ID: 24837773
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 30; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 8. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy.
    Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW.
    Clin Infect Dis; 2006 Feb 01; 42(3):315-9. PubMed ID: 16392073
    [Abstract] [Full Text] [Related]

  • 9. Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study.
    Ami N, Eyal N, Asaf B, Chen A, Adi B, Drorit A, Neta P, Hajar D, Stav R, Eli S.
    J Travel Med; 2021 Dec 29; 28(8):. PubMed ID: 34101817
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak.
    Abedi GR, Mutuc JD, Lawler J, Leroy ZC, Hudson JM, Blog DS, Schulte CR, Rausch-Phung E, Ogbuanu IU, Gallagher K, Kutty PK.
    Vaccine; 2012 Nov 19; 30(49):7052-8. PubMed ID: 23041123
    [Abstract] [Full Text] [Related]

  • 12. Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers.
    Hyle EP, Rao SR, Bangs AC, Gastañaduy P, Fiebelkorn AP, Hagmann SHF, Walker AT, Walensky RP, Ryan ET, LaRocque RC.
    JAMA Pediatr; 2020 Feb 01; 174(2):e194515. PubMed ID: 31816033
    [Abstract] [Full Text] [Related]

  • 13. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM.
    J Infect Dis; 2004 Jul 01; 190(1):83-90. PubMed ID: 15195246
    [Abstract] [Full Text] [Related]

  • 14. Determinants of students' willingness to accept a measles-mumps-rubella booster vaccination during a mumps outbreak: a cross-sectional study.
    Donkers HW, Hautvast JL, Akkermans RP, Swaan CM, Ruijs WL, Hulscher ME.
    BMC Public Health; 2015 Jun 20; 15():575. PubMed ID: 26092263
    [Abstract] [Full Text] [Related]

  • 15. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N, Jansson UB, Alm B.
    Vaccine; 2006 Jul 26; 24(31-32):5800-5. PubMed ID: 16765490
    [Abstract] [Full Text] [Related]

  • 16. Measles, mumps and rubella: control by vaccination.
    van Druten JA, de Boo T, Plantinga AD.
    Dev Biol Stand; 1986 Jul 26; 65():53-63. PubMed ID: 3556777
    [Abstract] [Full Text] [Related]

  • 17. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R, Svensson E, Trollfors B, Borres MP.
    Acta Paediatr; 2004 Sep 26; 93(9):1232-7. PubMed ID: 15384890
    [Abstract] [Full Text] [Related]

  • 18. Do children who receive an 'early dose' of MMR vaccine during a measles outbreak return for their regularly scheduled dose? A retrospective population-based study.
    Guo X, Simmonds KA, Svenson J, MacDonald SE.
    BMJ Open; 2016 Aug 31; 6(8):e012803. PubMed ID: 27580838
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct 31; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P, Baudin M.
    Vaccine; 2012 Apr 26; 30(20):3082-9. PubMed ID: 22406278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.